Vor Biopharma
VOR
Market cap $45.8M

0.6700 USD

-0.0110

1.62%

At close Oct 9, 4:00 PM EDT

Pre-market

0.6900

+0.0200

2.99%

1 day

-1.62%

5 days

-1.47%

1 month

-38.53%

3 months

-26.39%

6 months

-67.94%

Year to date

-69.96%

1 year

-64.74%

5 years

-98.21%

About: Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.

Employees: 168

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

1% more funds holding

Funds holding: 69 [Q1] → 70 (+1) [Q2]

5% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 21

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

6.79% less ownership

Funds ownership: 86.66% [Q1] → 79.87% (-6.79%) [Q2]

15% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 20

61% less capital invested

Capital invested by funds: $140M [Q1] → $54.5M (-$85.5M) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$3

348%

upside

Avg. target

$10.83

1,517%

upside

High target

$17.50

2,512%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

JMP Securities Silvan Tuerkcan 36% 1-year accuracy 14 / 39 met price target	1,691%upside $12	Market Outperform Reiterated	6 Sept 2024
HC Wainwright & Co. Swayampakula Ramakanth 21% 1-year accuracy 26 / 123 met price target	2,512%upside $17.50	Buy Reiterated	6 Sept 2024
Barclays Carter Gould 57% 1-year accuracy 21 / 37 met price target	348%upside $3	Overweight Maintained	14 Aug 2024

See Analyst Rankings

Financial journalist opinion

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join the Vor Bio leadership team and will report directly to the company's President and Chief Executive Officer, Dr. Robert Ang.

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

Thursday, Vor Biopharma Inc. VOR announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory acute myeloid leukemia (AML) receiving trem-cel followed by Mylotarg.

What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit.

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2024, and provided a corporate update.

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 31, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 1,250 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 1,875 shares of Vor Bio's common stock to one newly hired employee. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 3,000 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 4,500 shares of Vor Bio's common stock to three newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of June 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 1,000 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 1,500 shares of Vor Bio's common stock to one newly hired employee. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31, 2024, and provided a business update.

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

Vor Bio to Participate in Upcoming Investor Conferences

See News Rankings

Charts implemented using Lightweight Charts™